Helixmith Co. Ltd Cash Flow Conversion Efficiency

Latest as of June 2026: -0.010x

Helixmith Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, Helixmith Co. Ltd (084990) has a cash flow conversion efficiency ratio of -0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.38 Billion ≈ $-938.56K USD) by net assets (₩138.26 Billion ≈ $93.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Helixmith Co. Ltd (2010–2025)

Cash flow conversion efficiency of Helixmith Co. Ltd from 2010 to 2025. This chart illustrates how Helixmith Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 084990 share price today for real-time trading data and today's change.

Helixmith Co. Ltd Cash Flow Conversion Ratio Explained

Helixmith Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Helixmith Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Helixmith Co. Ltd ranked by their cash flow conversion efficiency. Also see Helixmith Co. Ltd (084990) total market value for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Swiss Steel Holding AG
SW:STLN
-0.244x
Yuyu Pharma
KO:000220
0.006x
Mono Next Public Company Limited
BK:MONO
0.696x
Feerum S.A.
WAR:FEE
0.073x
Incross Co. Ltd
KQ:216050
0.093x
HLV LIMITED
NSE:HLVLTD
0.007x
M2I Corporation
KQ:347890
0.021x
IHQ Inc
KO:003560
0.072x

Annual Cash Flow Conversion Efficiency for Helixmith Co. Ltd (2010–2025)

The table below shows the annual cash flow conversion efficiency of Helixmith Co. Ltd from 2010 to 2025. Review Helixmith Co. Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ₩141.52 Billion
≈ $95.91 Million
₩-6.90 Billion
≈ $-4.67 Million
-0.049x +58.59%
2024-12-31 ₩142.04 Billion
≈ $96.26 Million
₩-16.72 Billion
≈ $-11.33 Million
-0.118x +30.11%
2023-12-31 ₩153.72 Billion
≈ $104.18 Million
₩-25.89 Billion
≈ $-17.54 Million
-0.168x +10.38%
2022-12-31 ₩216.80 Billion
≈ $146.92 Million
₩-40.74 Billion
≈ $-27.61 Million
-0.188x -10.96%
2021-12-31 ₩225.35 Billion
≈ $152.72 Million
₩-38.16 Billion
≈ $-25.86 Million
-0.169x +2.54%
2020-12-31 ₩276.30 Billion
≈ $187.25 Million
₩-48.01 Billion
≈ $-32.54 Million
-0.174x +17.25%
2019-12-31 ₩195.57 Billion
≈ $132.53 Million
₩-41.07 Billion
≈ $-27.83 Million
-0.210x -108.92%
2018-12-31 ₩133.87 Billion
≈ $90.72 Million
₩-13.46 Billion
≈ $-9.12 Million
-0.101x -538.11%
2017-12-31 ₩164.45 Billion
≈ $111.45 Million
₩-2.59 Billion
≈ $-1.76 Million
-0.016x -9.76%
2016-12-31 ₩170.93 Billion
≈ $115.84 Million
₩-2.45 Billion
≈ $-1.66 Million
-0.014x -188.31%
2015-12-31 ₩67.20 Billion
≈ $45.54 Million
₩1.09 Billion
≈ $740.06K
0.016x +9598.28%
2013-12-31 ₩66.97 Billion
≈ $45.38 Million
₩11.22 Million
≈ $7.60K
0.000x +100.30%
2012-12-31 ₩64.45 Billion
≈ $43.68 Million
₩-3.58 Billion
≈ $-2.43 Million
-0.056x -26.50%
2011-12-31 ₩49.78 Billion
≈ $33.74 Million
₩-2.19 Billion
≈ $-1.48 Million
-0.044x +12.11%
2010-12-31 ₩52.72 Billion
≈ $35.73 Million
₩-2.64 Billion
≈ $-1.79 Million
-0.050x --

About Helixmith Co. Ltd

KQ:084990 Korea Food & Tobacco
Market Cap
$40.01 Million
₩59.04 Billion KRW
Market Cap Rank
#22531 Global
#1454 in Korea
Share Price
₩3700.00
Change (1 day)
+2.21%
52-Week Range
₩2805.00 - ₩9470.00
All Time High
₩167270.44
About

Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological… Read more